Keros Therapeutics, Inc.
NASDAQ:KROSBiotechnology
+$0.13 today
- Market cap
- $235.49M
- Beta
- 0.96
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$2.29
Volume 0.55M
Average 0.36M
KROS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Keros Therapeutics, Inc.NASDAQ: KROS
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $16.1M fell 67.0% year over year, behind the -47.3% change in trailing-twelve-month research & development. Sequentially, it fell 10.1% from the prior quarter. Over 3 fiscal years it compounded at +14.1% a year.
Context
- Research & development amounted to 53.1% of revenue in FY2025, down 4837.8 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -67.0% toward the trailing-twelve-month pace of -47.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 129.64M USD
- Year-over-year change
- -25.3%
- 4-year CAGR
- +23.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 129.64M | -25.3% |
| FY2024 | 2024-12-31 | 173.63M | +28.4% |
| FY2023 | 2023-12-31 | 135.26M | +55.0% |
| FY2022 | 2022-12-31 | 87.27M | +58.3% |
| FY2021 | 2021-12-31 | 55.14M | — |
Research & Development vs competitors
How KROS compares with its peers on the latest reported figures
- KROS's LTM Mar 2026 research & development of $97.03M is the 5th highest of the 10 companies compared; the peer median is $84.33M.
- Its year-over-year change of -47.3% is the lowest of 10, against a peer median of +33.3%.
- Research & development amounts to 292.4% of revenue for KROS, versus a peer median of 221.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $228.65M | +12.8% | -2.0% | 260.4% | |
| LTM Mar 2026 | $220.82M | +62.1% | +69.0% | — | |
| LTM Mar 2026 | $176.31M | +40.8% | +24.2% | — | |
| LTM Mar 2026 | $123.67M | +33.3% | +31.4% | 249.4% | |
| LTM Mar 2026 | $97.03M | -47.3% | +14.1% | 292.4% | |
| LTM Mar 2026 | $84.33M | +24.0% | +11.4% | 4593.1% | |
| LTM Mar 2026 | $69.1M | -13.8% | -14.9% | 194.4% | |
| LTM Mar 2026 | $37.44M | +64.5% | +11.3% | — | |
| LTM Mar 2026 | $36.54M | +41.7% | -17.9% | 12.2% | |
NAGENiagen Bioscience Inc | LTM Mar 2026 | $6.55M | +26.5% | +9.5% | 5.0% |
| Peer median (excluding KROS) | $84.33M | +33.3% | +11.3% | 221.9% | |
Competitors are the stored peer set for KROS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 20.1M | 0 | 151K | 3.55M | 244.06M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.51M |
| Gross Profit | 20.1M | 0 | 151K | 3.55M | 242.55M |
| Gross Margin | 100.0% | — | 100.0% | 100.0% | 99.4% |
| Research & Development | 55.14M | 87.27M | 135.26M | 173.63M | 129.64M |
| Selling, General & Admin | 21.33M | 27.53M | 34.83M | 40.75M | 46.85M |
| Operating Expenses | 76.47M | 114.79M | 170.09M | 214.38M | 171.93M |
| Depreciation & Amortization | 378K | 674K | 815K | 1.23M | 1.51M |
| EBITDA | (56.35M) | (104M) | (152.18M) | (185.82M) | 93.41M |
| EBITDA Margin | -280.4% | — | -100779.5% | -5234.5% | 38.3% |
| Operating Income | (56.37M) | (114.79M) | (169.94M) | (210.83M) | 70.62M |
| Operating Margin | -280.5% | — | -112543.7% | -5939.0% | 28.9% |
| Interest Income | 0 | 1K | 0 | 0 | 0 |
| Interest Expense | 4K | 1K | 0 | 0 | 0 |
| Other Income / Expenses | (360K) | 10.11M | 16.95M | 23.78M | 21.27M |
| Income Before Tax | (56.73M) | (104.68M) | (152.99M) | (187.05M) | 91.9M |
| Pre-Tax Margin | -282.3% | — | -101319.2% | -5269.1% | 37.7% |
| Income Tax Expense | 2.01M | 0 | 0 | 300K | 4.88M |
| Net Income | (58.74M) | (104.68M) | (152.99M) | (187.35M) | 87.01M |
| Net Margin | -292.3% | — | -101319.2% | -5277.5% | 35.7% |
| EPS (Basic) | (2.52) | (4.15) | (5.20) | (5.00) | 2.34 |
| EPS (Diluted) | (2.52) | (4.15) | (5.20) | (5.00) | 2.30 |
| Weighted Avg Shares | 23.33M | 25.24M | 29.45M | 37.44M | 37.22M |
| Weighted Avg Shares (Diluted) | 23.33M | 25.24M | 29.45M | 37.44M | 37.86M |
Keros Therapeutics, Inc.
NASDAQ:KROS
Intrinsic Alpha fair value
Locked
Current Price
$12.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.